INDEX / DIRECTORY / TEVA PHARMACEUTICALS

Teva Pharmaceuticals🇮🇱

Pharmaceuticals 114 CITED SOURCES UPDATED 2026-07-18
BDS-1000 Score 659 /1000 B Tier B - Severe
Military ↗ 0.50 Digital ↗ 0.05 Economic ↗ 9.40 Political ↗ 5.14

OpenIntel is reader-funded - no sponsors, no institutional money. Support OpenIntel →

Key Findings

  • Economic: Independent monitors (Who Profits, AFSC Investigate) list Teva under “Economic Exploitation,” documenting that Paris Protocol trade arrangements give the company tariff- and checkpoint-free access to a structurally captive Palestinian pharmaceutical market.1
  • Military: Teva has been identified as a corporate participant in the IDF’s “Adopt-a-Battalion” reservist-sponsorship program and donated medicines, baby-food compounds, computers and other equipment to the IDF following the 7 October 2023 attacks.23
  • Political: Teva’s CEO publicly described the company as “the national pharmaceutical company of Israel” after 7 October 2023, and Teva issued a public “Standing with Israel” statement.2
  • Not found: A Norwegian government-commissioned KPMG review (December 2024) found “no demonstrated presence, production or other activity” by Teva in the occupied Palestinian territories, and no public evidence was identified across any of the four domain audits of Teva manufacturing weapons, tactical/mil-spec products, or supplying Israeli defence-prime contractors.4

Target Profile

FieldDetail
Company NameTeva Pharmaceutical Industries Ltd.
JurisdictionIsrael - legal domicile and headquarters in Petah Tikva, Israel51
Headquarters5 Basel St., Petah Tikva, Israel51
SectorGeneric and specialty pharmaceuticals - manufacturing, R&D, active pharmaceutical ingredients (APIs), and global distribution
OwnershipPublicly traded on NASDAQ, the NYSE, and the Tel Aviv Stock Exchange; majority-institutional shareholder base; no Israeli state equity stake, golden share, or dual-class voting structure was identified51
Key Executives / GovernanceCEO Richard Francis (in role since January 2023), who publicly called Teva “the national pharmaceutical company of Israel” after 7 October 20232; board member Amir Elstein, also Chairman of Tower Semiconductor and Chairman of the Israel Democracy Institute6; Hadar Mama, director of Teva’s Israeli logistics subsidiary Salomon, Levin & Elstein (SLE), who served as an active IDF reservist in Gaza while continuing in his corporate role2
Israeli-Nexus SummaryIsraeli-founded, Israeli-domiciled pharmaceutical major that benefits from captive-market economic dynamics in the Occupied Palestinian Territories and from reservist/donation-based ties to the IDF, but shows no documented evidence of arms manufacturing, defence-prime supply integration, or military/intelligence technology contracting

Key Facts:

Executive Summary

Teva Pharmaceutical Industries Ltd. is an Israeli-founded and Israeli-domiciled multinational generics manufacturer whose relationship to Israel and the Palestinian territories is documented across economic, political, digital, and military-adjacent vectors - but with markedly uneven weight between them. The strongest and best-evidenced vector by far is economic: Teva is repeatedly named by Who Profits and the American Friends Service Committee as a beneficiary of Paris Protocol trade asymmetries that create a structurally captive Palestinian pharmaceutical market, in which Teva and a small number of other Israeli-origin manufacturers enjoy customs- and checkpoint-free access while Palestinian generic producers face licensing and export burdens.151112

The political and military vectors are documented but comparatively modest in character, resting mainly on wartime solidarity messaging, corporate participation in IDF reservist-support and donation programs, and a subsidiary director’s dual role as an active reservist during the Gaza war, rather than on defence contracts or state-security branding.2313 CEO Richard Francis’s post–7 October 2023 characterization of Teva as “the national pharmaceutical company of Israel,” combined with Teva’s participation in the “Adopt-a-Battalion” corporate-sponsorship framework and its funding of psychological-support programs for IDF-linked organisations, constitutes the clearest documented evidence of a values-aligned relationship between Teva and the Israeli state during the current conflict.23

What is explicitly not supported by the evidence is any nexus to weapons manufacturing, tactical/mil-spec product variants, supply-chain integration with Israeli defence primes (Elbit Systems, IAI, Rafael, IMI Systems), or contracted IT/surveillance services to Israeli military or intelligence agencies. No public evidence was identified of Teva appearing in the UN OHCHR settlement-business database in its finalized 2020, 2023, or September 2025 editions, and Teva was not named in UN Special Rapporteur Francesca Albanese’s July 2025 “economy of genocide” report. A KPMG-commissioned due-diligence review for a Norwegian public hospital procurement authority - arguably the single most rigorous third-party check available in this record - found “no demonstrated presence, production or other activity” by Teva in the occupied Palestinian territories as of December 2024, and Norwegian procurement authorities subsequently declined to terminate Teva contracts.4

Teva’s digital footprint shows conventional enterprise-technology relationships (AWS cloud infrastructure, ISO 27001 certification, an Israeli-background Global CISO) and civilian, general-purpose AI drug-discovery partnerships (AION Labs, the Israel BioToken Factory Initiative) with no evidence of military, surveillance, or targeting application.14151689101718 Civil-society scrutiny of Teva is real and escalating - Who Profits, AFSC, the StopTeva coalition, and a growing wave of European boycott campaigns in the UK, Ireland, Italy, and Spain’s Canary Islands have all targeted the company - but this scrutiny centres overwhelmingly on the captive-market economic critique and on wartime solidarity symbolism, not on documented military-industrial supply.1920212223242526

Taken together, this evidence record produces a BRS of 659 (Tier B, Severe), driven almost entirely by the Economic domain (Economic = 9.40), with Political contributing meaningfully (Political = 5.14) and Military and Digital contributing only marginally (Military = 0.50; Digital = 0.05). The tier reflects a company whose economic entanglement with the occupation is well-evidenced and structural, while its military and digital involvement remain thin, largely humanitarian/wartime-solidarity in character, and explicitly disclaimed by an independent third-party audit.

Timeline of Relevant Events

DateEvent
1901Predecessor wholesale drug business (later “SLE Ltd.”) founded in Jerusalem.51
1976Modern Teva Pharmaceutical Industries Ltd. formed via merger of three Israeli pharmaceutical companies.51
1982Teva’s Kfar Saba manufacturing plant receives FDA approval; Teva begins trading on NASDAQ.51
2016 (by)Teva subsidiary MBT Biological Laboratories, previously operating in the Atarot industrial zone (East Jerusalem/West Bank), documented as relocated to Beit Shemesh inside Israel; reporting links the move to boycott pressure.27
2019Teva sells its Shoham logistics centre to Israeli real-estate firm Amot Investments Ltd. for approximately NIS 445m ($127m), leasing it back for 10 years; Amot separately holds an industrial asset in the Ariel settlement (indirect landlord link only - Teva itself was not found to use the Ariel asset).282930
11 October 2023Teva issues public “Standing with Israel” statement following the 7 October attacks.213
October 2023Teva donates medicines, baby-food compounds and computers to the IDF; roughly 1.5 tons of employee-donated equipment collected at five Teva Israel sites.2
February 2024CEO Richard Francis tells the Times of Israel that Teva’s Israeli production and distribution remained “largely unaffected” by the war, citing Israel as ~2% of global revenue and under 8% of global production.13
March 2024Protest of over 30 activists outside a UK Teva facility calling for a boycott (“Boycott Teva Pharma No to Apartheid Drugs!”).22
December 2024KPMG “Targeted Research” report commissioned by Norway’s Sykehusinnkjøp HF finds no demonstrated Teva presence, production, or activity in the occupied Palestinian territories.4
September 2025UN OHCHR updates its settlement-business database (158 enterprises); Teva remains unlisted.31
November 2025Peoples Dispatch reports Europe’s Palestine solidarity movement strengthening its call to boycott Teva.23
February 2026Healthcare boycott campaign targeting Teva reported in Spain’s Canary Islands.26

Corporate Overview

Teva Pharmaceutical Industries Ltd. is structured as an Israeli-domiciled global parent with manufacturing, R&D, and distribution operations spanning generics, specialty pharmaceuticals, biosimilars, and APIs.51 Within Israel, its principal operating footprint includes manufacturing/R&D sites in Kfar Saba and Netanya, an API/raw-materials plant at Neot Hovav (Ramat Hovav) near Beersheba, and headquarters in Petah Tikva.51 In-country distribution and logistics run through its wholly-owned subsidiary Salomon, Levin & Elstein Ltd. (SLE), which historically operated the large Shoham logistics centre (sold to Amot Investments in 2019 and leased back) and which Who Profits identifies as benefiting from tariff- and checkpoint-free access to the Palestinian market under the Paris Protocol trade regime.712829 A former Teva subsidiary, MBT Biological Laboratories, operated in the Atarot industrial zone of East Jerusalem - territory documented in the Peace Now settlement database as occupied - before relocating to Beit Shemesh inside Israel by no later than 2016.27 No public evidence was identified of any other current Teva subsidiary or franchise operating inside a West Bank settlement or the Golan Heights; a separately-owned footwear company trading as “Teva Naot” with stores reported in West Bank settlements is confirmed via distinct corporate identifiers to be an unrelated company, flagged here only to prevent misattribution.

Domain Summaries

Military: Military

Mechanism of Involvement

Teva has been identified as a corporate participant in the IDF’s “Adopt-a-Battalion” program, which enables corporate sponsorship of military units.3 Following the 7 October 2023 attacks, Teva donated essential medicines, baby-food compounds, and computers to the IDF, framed by the company as humanitarian rather than procurement activity.232 CEO Richard Francis publicly stated that Teva is “the national pharmaceutical company of Israel.”2 Teva Pharmaceuticals USA separately holds U.S. Department of Defense contracts for adenovirus vaccines (e.g., a $330,314 delivery order in March 2025) - these are civilian-market U.S. federal contracts, not Israeli defence end-use.33 Certain Teva generics (atropine sulfate, morphine, epinephrine, ciprofloxacin, amoxicillin) are standard products stocked by militaries worldwide, but no evidence was identified of purpose-built military or tactical variants.

Counter-Arguments and Evidence Limits

No public evidence was identified of verified contracts, framework agreements, or memoranda of understanding between Teva and the Israeli Ministry of Defence, Israel Prison Service, or Israel Border Police beyond documented charitable donations. No public evidence was identified that Teva’s commercial catalogue triggers ITAR, Wassenaar, or EU Dual-Use Regulation controls. No public evidence was identified of Teva supplying components, sub-systems, or manufacturing services to Elbit Systems, IAI, Rafael, or IMI Systems, nor of any joint-development or co-production arrangement with an Israeli defence prime. Teva does not manufacture weapons, munitions, vehicles, drones, or heavy machinery, and no public evidence was identified of any government decision to grant, deny, or revoke export licences for Teva products to Israeli military end-users.

Named Entities and Evidence Map

Digital: Digital

Mechanism of Involvement

Teva is a founding pharmaceutical partner of AION Labs, an Israeli AI-drug-discovery venture studio launched in 2021 with AstraZeneca, Merck KGaA, Pfizer, and AWS as a technology partner.910 Teva is also a named industry partner in the “Israel BioToken Factory Initiative” (IBFI), a roughly NIS 70 million national AI-infrastructure consortium announced July 2026 involving the Israel Innovation Authority, NVIDIA, Sheba Medical Center, and several Israeli universities, building shared AI infrastructure for drug discovery and clinical decision support.1718 Teva’s Digihaler digital-inhaler platform runs on AWS cloud infrastructure with implementation partner Onica.8 Teva’s Global CISO, Ilan Abadi, has an Israeli security-sector career background - CISO at the Israel National Police and at Ness Technologies, and Head of Information Security at YES Television - prior to joining Teva; no direct Unit 8200 affiliation is documented for him.1516 Teva’s 10-K cybersecurity disclosure names no specific vendors and states only that the company is ISO 27001-certified and engages unspecified third-party consultants.14

Counter-Arguments and Evidence Limits

These AI collaborations (AION Labs, IBFI) are general-purpose biomedical and drug-discovery platforms with explicit civilian pharmaceutical application; no evidence connects them to targeting, kill-chain, or military decision-support use.9101718 No public evidence was identified of a direct licensing or integration relationship between Teva and Check Point, Wiz, SentinelOne, CyberArk, NICE, Verint, Claroty, or Palo Alto Networks. No public evidence was identified of Teva’s use of Israeli-origin facial-recognition, biometric, or surveillance products, of Teva’s participation in Project Nimbus, or of Teva providing autonomous-targeting or threat-detection systems to Israeli military or security forces. No public evidence was identified of Teva AI models trained on surveillance-derived or occupied-territory population data.

Named Entities and Evidence Map

Economic: Economic

Mechanism of Involvement

Teva’s Israeli distribution runs through wholly-owned subsidiary SLE, which Who Profits and AFSC Investigate describe as benefiting from Paris Protocol trade asymmetries - tariff- and checkpoint-free access to the Palestinian market, no requirement for Arabic-language labelling, and reduced competition from Palestinian generics due to Israeli Ministry of Health registration restrictions.7151112 A 2012 Who Profits sector report names Teva as one of four dominant Israeli-origin pharmaceutical companies benefiting from this structurally captive market.11 A 2025-dated source citing a Palestinian pharmacist asserts continued Israeli/Teva market dominance producing shortages, including of tamoxifen, in the Occupied Palestinian Territory.38 Teva’s Shoham logistics facility, sold in 2019 to Amot Investments, creates an indirect landlord relationship since Amot separately holds an industrial asset in the Ariel settlement - Teva itself was not found to hold or use that asset.282930 Teva subsidiary MBT Biological Laboratories formerly operated in the Atarot industrial zone (East Jerusalem) before relocating to Beit Shemesh, discontinued no later than 2016.27

Counter-Arguments and Evidence Limits

A KPMG-commissioned due-diligence review for Norway’s Sykehusinnkjøp HF found “no demonstrated presence, production or other activity in occupied Palestinian areas” by Teva as of December 2024 - directly contrasting with the older (2012-dated) Who Profits “captive economy” analysis, whose underlying data has not been substantively refreshed.411 No public evidence was identified of Teva sourcing Israeli agricultural exports, holding a portfolio stake in other Israeli companies, or holding Israeli sovereign/war bonds. No public evidence was identified of Teva appearing in PAX’s “Companies Arming Israel and Their Financiers” report or in the accessible portions of the “Don’t Buy Into Occupation” coalition report. Teva’s own reporting indicates Israel constitutes a small share of its global production footprint. Separately, Teva Pharmaceuticals USA agreed to pay $450 million in a False Claims Act settlement with the U.S. DOJ over kickback allegations - an unrelated U.S. regulatory-compliance matter, not tied to Israel/Palestine conduct.39

Named Entities and Evidence Map

Political: Political

Mechanism of Involvement

Three days after the 7 October 2023 attacks, Teva issued a “Standing with Israel” statement affirming solidarity, with no reference to Palestinian civilians, pivoting to business-continuity assurances.213 CEO Richard Francis told the Times of Israel in February 2024 that Teva’s Israeli operations had performed “extraordinary[ly]” through wartime conditions.13 Teva participated in the IDF-linked “Adopt-a-Battalion” reservist-welfare program (though it is no longer listed as an active partner on the program’s current site, with discontinuation date unclear).32 Hadar Mama, director of Teva’s logistics subsidiary SLE, served as an active IDF reservist in Gaza in December 2023 while continuing in his corporate leadership role - described by campaign sources as a documented conflict-of-interest concern to which no company response was located.2 Roughly 1.5 tons of IDF-directed equipment was collected from Teva employees at five Israeli sites by late October 2023.2

Counter-Arguments and Evidence Limits

No public evidence was identified of a Teva statement addressing Palestinian civilian casualties, Gaza’s humanitarian conditions, or ICJ/ICC proceedings - the company’s only conflict-era public messaging identified is the pro-Israel October 2023 statement and subsequent operational/financial commentary.213 No public evidence was identified of Teva disciplining any employee for pro-Palestinian speech, of algorithmic content-moderation controversy, or of a formal SEC shareholder resolution on Israel/Palestine human-rights due diligence. Teva-donated medicines have also been included in humanitarian shipments into Gaza via Direct Relief, indicating some countervailing humanitarian channel activity alongside the wartime solidarity messaging.2 Civil-society boycott campaigns against Teva (UK, Italy, Canary Islands, broader European coordination) have intensified but rest primarily on the economic captive-market critique and wartime-solidarity symbolism rather than on newly-uncovered military contracts.22242526

Named Entities and Evidence Map

BDS-1000 Score (V4)

DomainIMPV-Domain Score
Military3.502.003.500.50
Digital1.501.001.500.05
Economic9.408.509.009.40
Political7.205.008.005.14

The BRS is driven almost entirely by Economic (V_MAX = 9.40), reflecting the well-evidenced, structural nature of Teva’s captive-Palestinian-market economic exposure under the Paris Protocol regime, as documented by Who Profits, AFSC, and a 2012 sector-wide report, and only partially offset by a more recent (2024) KPMG finding of no direct OPT operational presence. Political contributes a secondary weight from wartime solidarity messaging, IDF-adjacent reservist and donation programs, and a subsidiary director’s dual military role. Military and Digital remain near-floor, reflecting the near-total absence of arms-manufacturing, defence-prime, or military-technology evidence despite extensive search. Scores follow the scale-free V4 method: Impact (I) captures the type of activity, Magnitude (M) its scale, and Proximity (P) its directness to the conflict; all figures were fixed through the corpus’s human-vetting process and are reproduced here unaltered.

Methodology Note

End Notes

Footnotes

  1. https://www.whoprofits.org/companies/company/4212 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14

  2. https://stopteva.nl/wp-content/uploads/2025/07/20250615_Teva_and_the_IDF_Repill-.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21

  3. https://israel365news.com/310744/civilians-companies-invited-adopt-idf-battalion ↩ ↩2 ↩3 ↩4 ↩5

  4. https://www.sykehusinnkjop.no/4b01f0/siteassets/bilder/nyheter/2024/gransking-teva/kpmg-targeted-research-teva-december-2024.pdf ↩ ↩2 ↩3 ↩4 ↩5

  5. https://investigate.afsc.org/company/teva-pharmaceutical-industries ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  6. https://www.tevapharm.com/our-company/leadership-governance/board-of-directors/amir-elstein ↩ ↩2

  7. https://www.whoprofits.org/companies/company/4243 ↩ ↩2 ↩3 ↩4

  8. https://www.tevausa.com/news-and-media/press-releases/teva-amazon-web-services-and-onica-announce-collaboration-to-support-tevas-digihaler-portfolio/ ↩ ↩2 ↩3

  9. https://en.wikipedia.org/wiki/AION_Labs ↩ ↩2 ↩3 ↩4 ↩5

  10. https://aws.amazon.com/blogs/industries/aws-joins-pharma-and-biotech-leaders-in-launching-aion-labs-to-transform-therapeutics/ ↩ ↩2 ↩3 ↩4 ↩5

  11. https://www.whoprofits.org/writable/uploads/publications/1668626890_1aa4455a6a4cc3b32b5d.pdf ↩ ↩2 ↩3 ↩4

  12. https://bdsmovement.net/news/captive-economy-pharmaceutical-industry-and-israeli-occupation ↩ ↩2

  13. https://www.timesofisrael.com/teva-ceo-says-production-and-distribution-in-israel-remain-largely-unaffected-by-war/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  14. https://www.board-cybersecurity.com/annual-reports/tracker/20250205-teva-pharmaceutical-industries-ltd-cybersecurity-10k ↩ ↩2

  15. https://cybeready.com/hi-5-with-ilan-abadi/ ↩ ↩2 ↩3

  16. https://cyberstartupobservatory.com/cybersecurity-leaders-ilan-abadi-vp-ciso-teva-pharmaceuticals/ ↩ ↩2 ↩3

  17. https://natlawreview.com/press-releases/israel-innovation-authority-invests-approx-nis-70-million-national ↩ ↩2 ↩3

  18. https://www.synbiobeta.com/read/the-israel-innovation-authority-to-invest-approximately-nis-70-million-in-national-infrastructure-for-ai-models-based-on-biological-data ↩ ↩2 ↩3

  19. https://www.middleeastmonitor.com/20200212-un-blacklists-112-companies-with-ties-to-illegal-israel-west-bank-settlements/ ↩

  20. https://kiaoragaza.wordpress.com/2020/02/13/un-blacklists-112-companies-with-ties-to-israels-illegal-west-bank-settlements/ ↩

  21. https://actionnetwork.org/petitions/letter-to-un-global-compact-for-removal-of-teva-pharmaceuticals-from-list-of-participants ↩

  22. https://freedomnews.org.uk/2024/03/04/ongoing-protest-at-israeli-pharmaceutical-factory/ ↩ ↩2 ↩3 ↩4

  23. https://peoplesdispatch.org/2025/11/07/europes-palestine-solidarity-movement-strengthens-call-to-boycott-israeli-pharmaceutical-company-teva/ ↩ ↩2 ↩3

  24. https://iacenter.org/2025/11/15/boycott-teva-campaign/ ↩ ↩2 ↩3

  25. https://www.newarab.com/news/italian-bds-campaign-targets-israeli-drugmaker-teva ↩ ↩2 ↩3

  26. https://tenerifeweekly.com/2026/02/27/social-groups-drive-healthcare-boycott-of-teva-pharmaceuticals-in-the-canaries-over-support ↩ ↩2 ↩3 ↩4

  27. https://peacenow.org.il/en/settlements/settlement159-en ↩ ↩2 ↩3 ↩4

  28. https://www.fiercepharma.com/pharma/teva-sheds-logistics-center-for-127m-after-2-years-2-about-faces ↩ ↩2 ↩3 ↩4

  29. https://en.globes.co.il/en/article-mmot-buys-tevas-logistics-center-1001303332 ↩ ↩2 ↩3 ↩4

  30. https://investigate.afsc.org/company/amot-investments ↩ ↩2 ↩3

  31. https://www.ohchr.org/en/press-releases/2025/09/un-human-rights-office-updates-database-businesses-involved-israeli ↩

  32. https://www.declassifieduk.org/the-israeli-firm-aiding-the-nhs-and-idf ↩

  33. https://www.govchime.com/market-intelligence/awards/CONT_AWD_SPE2DP25F4433_9700_SPE2DP20D0002_9700 ↩

  34. https://www.facebook.com/ThankIsraeliSoldiers/posts/we-were-honored-to-partner-with-teva_israel_-teva-pharmaceuticals-on-a-beautiful/1032698839045059 ↩ ↩2

  35. https://www.tevel-tech.com/eyal-desheh-about/ ↩

  36. https://www.prnewswire.com/il/news-releases/migvax-appoints-eyal-desheh-former-teva-check-point-executive-as-chairman-301072256.html ↩

  37. https://ir.mobileye.com/corporate-governance/board-of-directors ↩

  38. https://historikereforpalestina.no/selskapsdatabasen/helse-og-farmasia/teva-pharmaceutical-industries-ltd/ ↩

  39. https://www.justice.gov/archives/ ↩